|
|
Survey on knowledge related to Alzheimer’s disease |
WANG Yiru1, WANG Siyao2, GUO Peng3, XUE Qiaodan2,4, LI Lixia5 |
1. School of Pharmaceutical Sciences,2. School of Basic Medical Sciences,4. School of Marxism, Capital Medical University, Beijing, 100069, China;3. Center for Cognitive Neurology, Department of Neurology,5. Department of Internal Medicine in International Medical Services, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China |
|
|
Abstract Objective To investigate the knowledge of social population about Alzheimer’s disease (AD) and the application status of non-pharmacological therapies in AD treatment, as well as the acceptance and demand for non-pharmacological therapies using the Internet platform. Methods A questionnaire and WeChat QR code of AD and its non-pharmacological therapy were prepared, and the questionnaires were filled in and submitted by scanning the QR code of WeChat questionnaire. Results A total of 587 valid questionnaires were received, with 161 males and 426 females. The most common symptoms of AD were memory decrease (513) and decreased thinking ability (480). The 368 cases had more knowledge about age and 308 cases about genetic inheritance as AD risk factors. Spearman correlation analysis showed that the awareness of AD main symptom and risk factors were negatively associated with age (P<0.001), and positively educational level and monthly income (P<0.01). Logistic regression found that age (OR 0.800, 95% CI 0.705-0.908, P=0.001), educational level (OR 1.557, 95% CI 1.344-1.804, P<0.001) and occupation (OR 1.082, 95% CI 1.003-1.167, P=0.040) were associated with the awareness of the AD main symptoms. The age (OR 0.669, 95% CI 0.581-0.770, P<0.001), educational level (OR 1.451, 95% CI 1.181-1.785, P<0.001) and monthly income (OR 1.246, 95% CI 1.072-1.448, P=0.004) were influential factores in the awareness of AD risk factors. Among the 90 respondents who had AD patients in their families, 86.7% expressed a strong or urgent need to change the troubles caused by AD to their families, 71.1% did not fully recognize, acknowledge, or understand non-pharmacological treatments for AD, and 82.2% of the respondents were willing to try non-pharmacological treatments by APP or other Internet ways. Conclusions The overall awareness rate of clinical manifestations and prevention knowledge of AD is low. At the same time, if people are eager to change the troubles caused by AD, they can consider using the Internet platform for AD education and try non-pharmacological treatment.
|
Received: 20 August 2024
|
|
|
|
|
[1] |
Long S, Benoist, C, Weidner W. World Alzheimer Report 2023: Reducing dementia risk: never too early, never too late[R]. London, England: Alzheimer’s Disease International, 2023:1-96.
|
[2] |
徐 勇,王 军,王虹峥,等. 2023中国阿尔茨海默病数据与防控策略[J]. 阿尔茨海默病及相关病,2023,6(3):175-192.
|
[3] |
Jia L, Quan M, Fu Y, et al. Dementia in China: epidemiology, clinical management, and research advances [J]. Lancet Neurol, 2020,19(1): 81-92.
|
[4] |
Athar T, Al Balushi K, Khan S A. Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease [J]. Mol Biol Rep,2021,48(7): 5629-5645.
|
[5] |
Solch R J, Aigbogun J O, Voyiadjis A G, et al. Mediterranean diet adherence, gut microbiota, and Alzheimer’s or Parkinson’s disease risk: a systematic review [J]. J Neurol Sci, 2022, 434: 120166.
|
[6] |
Bleibel M, El Cheikh A, Sadier N S, et al. The effect of music therapy on cognitive functions in patients with Alzheimer’s disease: a systematic review of randomized controlled trials[J]. Alzheimers Res Ther, 2023,15(1): 65.
|
[7] |
Park M, Song R, Ju K, et al. Effects of Tai Chi and Qigong on cognitive and physical functions in older adults: systematic review, meta-analysis, and meta-regression of randomized clinical trials [J]. BMC Geriatr, 2023, 23(1): 352.
|
[8] |
Zhang X X, Tian Y, Wang Z T, et al. The epidemiology of Alzheimer’s disease modifiable risk factors and prevention [J]. J Prev Alzheimers Dis, 2021, 8(3): 313-321.
|
[9] |
Scheltens P, de Strooper B, Kivipelto M, et al. Alzheimer’s disease [J]. Lancet, 2021, 397(10284): 1577-1590.
|
[10] |
Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer’s disease continuum [J]. Alzheimers Dement, 2023,19(2): 658-670.
|
[11] |
吴玉莲,杨晋如,程桂荣,等. 中国居民对阿尔茨海默病临床表现及危害识别[J]. 中国老年学杂志, 2019, 39(8): 1992-1996.
|
[12] |
Wang R Z, Yang Y X, Li H Q, et al. Genetically determined low income modifies Alzheimer’s disease risk [J]. Ann Transl Med, 2021, 9(15):1222.
|
[13] |
Adewale B A, Coker M M, Ogunniyi A, et al. Biomarkers and risk assessment of Alzheimer’s disease in low- and middle-income countries [J]. J Alzheimers Dis, 2023, 95(4): 1339-1349.
|
[14] |
Stern Y. Cognitive reserve [J]. Neuropsychologia, 2009, 47: 2015-2028.
|
[15] |
Guzman-Martinez L, Calfío C, Farias G A, et al. New frontiers in the prevention, diagnosis, and treatment of Alzheimer’s disease [J]. J Alzheimers Dis, 2021,82(s1):S51-S63.
|
[16] |
González-Madrid A, Calfío C, González A, et al. Toward prevention and reduction of Alzheimer’s disease [J]. J Alzheimers Dis, 2023,96(2): 439-457.
|
[17] |
Fonte C, Smania N, Pedrinolla A, et al. Comparison between physical and cognitive treatment in patients with MCI and Alzheimer’s disease [J]. Aging (Albany NY), 2019,11(10):3138-3155.
|
[18] |
López-Ortiz S, Valenzuela P L, Seisdedos M M, et al. Exercise interventions in Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials [J]. Ageing Res Rev, 2021,72: 101479.
|
|
|
|